Genentech, a member of the Roche Group (RHHBY), announced its decision to advance prasinezumab—a potential anti-alpha-synuclein antibody—into Phase III clinical development for early-stage Parkinson's disease. The decision is based on findings from the Phase IIb PADOVA study, as well as ongoing open-label extensions (OLEs) of both the PADOVA and Phase II PASADENA trials.
The ongoing PASADENA and PADOVA open-label extension (OLE) studies are evaluating the long-term safety and efficacy of prasinezumab in more than 750 individuals with early-stage Parkinson's disease.
Roche's Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.